Business Context and Reporting Period
This Form 8-K was filed by Vivos Therapeutics, Inc. on July 15, 2022, reporting events that occurred on July 14, 2022. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Littleton, Colorado. Its common stock trades on The NASDAQ Stock Market LLC under the symbol "VVOS."
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The material change reported is a regulatory milestone rather than a financial one. On July 14, 2022, the Company received multiple Class I clearances from the Therapeutic Goods Administration (TGA) of Australia. The TGA is a Tier 1 regulatory body. These clearances cover multiple indications for the Company's series of oral appliances, including the treatment of snoring and obstructive sleep apnea (mild, moderate, and severe) for both adults and children.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or a discussion of specific risks and contingencies beyond the context of the regulatory approval. The primary focus is the announcement of the TGA clearances, which is detailed further in the press release filed as Exhibit 99.1.
Investor Verification Checklist
- Verify the specific scope of the Class I clearances granted by the Australian TGA by reviewing the press release in Exhibit 99.1.
- Confirm the commercial implications of these clearances for the Company's oral appliance product line in the Australian market.
- Review the Company's most recent 10-Q or 10-K filing for current financial health, cash position, and burn rate, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on the commercialization timeline following this regulatory approval.